Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina.

Cancers (Basel) · 2022 · PMC9265690 · PMID 35805057

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In our report, even if no significant difference in EFSp was observed according to doses of ARA-C, all relapses occurred in the non-HD-ARAC group and survival results showed a trend to achieve better results in the group of patients treated with HDARA-C. 5.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.